Revenue + Forward P/E
Revolution Medicines, Inc. (RVMD) quarterly revenue and forward P/E
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$43.32B
Enterprise value
$40.23B
P/E ratio (TTM)
-26.61x
P/S ratio (TTM)
0.00x
P/B ratio
24.99x
EV/Sales
0.00x
EV/EBITDA
-30.50x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$0
Gross profit (TTM)
$-16.56M
Operating income (TTM)
$-1.18B
EBITDA (TTM)
$-1.09B
Net income (TTM)
$-1.13B
Free cash flow (TTM)
$-913.73M
Margins & returns
Gross margin
0.00%
Operating margin
0.00%
Profit margin
0.00%
Return on equity
-83.22%
Return on assets
-60.86%
Per-share metrics
EPS (TTM)
-$6.92
Dividend yield
0.00%
Beta
1.38
Capital structure
Cash & equivalents
$383.75M
Total debt
$158.70M
Net debt
$-225.04M
Shares outstanding
212.60M
Financial health
Current ratio
7.14
Debt / equity
0.10
Debt / assets
0.07
Interest coverage
-48.80
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.85B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.16B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.38B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.46B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $43.32B | -26.61x | 0.00x | -30.50x | - |